Natural History of Branch Retinal Vein Occlusion: An Evidence-Based Systematic Review

Rogers, Sophie; McIntosh, Rachel; Lim, Lyndell L; Mitchell, Paul; Cheung, Ning; Kowalski, Jonathan W.; Nguyen, Hannah; Wang, Jie Jin; Wong, Tien Yin

doi:10.1016/j.ophtha.2010.01.058

Cited by 379 publications

(291 citation statements)

References 33 publications

Supporting

Mentioning

270

Contrasting

Unclassified

Order By: Relevance

“…[30][31][32] Over a 1-year period, 5-15% of eyes developed ME, but of those with ME at baseline, 18-41% resolved. 33 When considering this benign course Figure 2 Comparison of functional and anatomical outcomes between the two groups. (a) The mean BCVA (logMAR) during follow-up periods between the two groups.…”

Section: Discussionmentioning

confidence: 99%

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Moon

Kim

Sagong

2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate efficacy and safety of combination therapy of intravitreal bevacizumab (IVB) with single simultaneous posterior subtenon triamcinolone acetonide (STA) for treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods This was a prospective, randomized, interventional comparative study conducted in 45 eyes with ME secondary to BRVO who were treated primarily with IVB 1.25 mg (23 eyes, IVB group) or combination therapy of IVB 1.25 mg with a single simultaneous STA 40 mg (18 eyes, IVB/STA group). Reinjections were performed with IVB if optical coherence tomography (OCT) showed recurrent ME associated with decreased visual acuity. The main outcome measurement was the number of additional IVB injections, and changes of best-corrected visual acuity (BCVA) and central macular thickness (CMT) during a 6-month follow-up period were compared. Results BCVA showed significant improvement in two groups at 6 months. In addition, CMT showed significant decrease in two groups at 6 months. No significant differences in the change of BCVA and CMT at 6 months after injection (P = 0.973, P = 0.639) were observed between the two groups. A statistically significant difference was found regarding the number of additional IVB injections (IVB group 0.96 ± 0.83; IVB/STA group 0.44 ± 0.70, P = 0.034).Conclusion Although combination therapy of IVB with a single simultaneous STA for treatment of ME secondary to BRVO did not affect the visual outcomes compared with IVB monotherapy, it had a benefit of reducing the number of additional IVB injections.

show abstract

Section: Discussionmentioning

confidence: 99%

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Moon

Kim

Sagong

2016

Eye

View full text Add to dashboard Cite

show abstract

“…1 RVO is an obstruction of the retinal venous system, and may involve the central retinal vein or a branch retinal vein. Possible causes are external compression or disease of the vein wall, for example, vasculitis.…”

Section: Introductionmentioning

confidence: 99%

“…1,3 Baseline visual acuity is moderately poor, ranging from 20/40 to o20/200 in both BRVO and CRVO eyes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The burden of disease of retinal vein occlusion: review of the literature

Laouri¹,

E²,

Looman³

et al. 2011

Eye

202

154

View full text Add to dashboard Cite

Retinal vein occlusion (RVO) is the second most common cause of vision loss due to retinal vascular disease. A literature review was undertaken to understand the epidemiology, clinical consequence, current practice patterns, and cost of RVO. Pertinent articles were identified by computerized searches of the English language literature in MEDLINE supplemented with electronic and manual searches of society/association proceedings and bibliographies of electronically identified sources. Populationbased studies report a prevalence rate of 0.5-2.0% for branch RVO and 0.1-0.2% for central RVO. The 15-year incidence rate is estimated to be 1.8% for branch RVO and 0.2% for central RVO. Patients with RVO report lower vision-related quality of life than those without ocular disease. Available treatment options are limited. Until recently there was no treatment for central RVO. Laser photocoagulation is only recommended for branch RVO in patients who have not experienced severe vision loss. Emerging evidence on the effectiveness of intravitreal anti-vascular endothelial growth factor therapy and dexamethasone intravitreal implant is promising. Information on the treatment patterns and cost of RVO is extremely limited with one retrospective analysis of secondary insurance payment data identified and limited to the United States population only. A better understanding of the economic and societal impact of RVO will help decision makers evaluate emerging medical interventions for this sight-threatening disease.

show abstract

“…[1][2][3] The terminology broadly includes retinal vein occlusion (RVO) where retinal vascular blockage involves the retinal veins, and retinal artery occlusion (RAO) where the blockage is at the retinal artery tributary. The prevalence of RVO is estimated to be 0.7-1.6% of the general population, 1,2 whereas RAO is much less common.…”

Section: Introductionmentioning

confidence: 99%

Associations of retinal artery occlusion and retinal vein occlusion to mortality, stroke, and myocardial infarction: a systematic review

Woo

Lip

2016

Eye

View full text Add to dashboard Cite

Retinal vascular events are perceived to be related to various cardiovascular complications. We conducted a systematic review to assess the relationship between retinal artery/vein occlusions (RAO/RVO) and the incidence of mortality, stroke, and myocardial infarction (MI). A comprehensive electronic literature search selected 93 relevant studies between 1992-2015: 16 articles qualified for inclusion (7 for mortality rate and MI, 11 for stroke). No published articles examined associations of RAO to mortality or MI, but only to stroke. Because of the heterogeneity of studies, no meta-analysis was performed. The association with mortality risk was highest at~34.7% in RVO subgroup; whereas for MI, the risk was comparatively lower at 3.9-5.7% for RVO. There was no significant difference in stroke rate when comparing central and branch RVO subgroups (6.5%), but was significantly higher at 19.6-25% in RAO. There is a positive association of retinal vascular events to mortality, stroke, and MI. RAO is associated with a higher risk of stroke. Given that RAO and RVO patients would generally present to ophthalmologists, their high cardiovascular risk should include a referral for cardiovascular assessment as part of their management protocol.

show abstract

Natural History of Branch Retinal Vein Occlusion: An Evidence-Based Systematic Review

Abstract: Visual acuity generally improved in eyes with BRVO without intervention, although clinically significant improvement beyond 20/40 was uncommon.

Cited by 379 publications

References 33 publications

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

The burden of disease of retinal vein occlusion: review of the literature

Associations of retinal artery occlusion and retinal vein occlusion to mortality, stroke, and myocardial infarction: a systematic review

Contact Info

Product

Resources

About